Bionomics Limited (NASDAQ:BNOX – Get Free Report) saw a significant increase in short interest in the month of June. As of June 15th, there was short interest totalling 388,300 shares, an increase of 410.2% from the May 31st total of 76,100 shares. Based on an average daily trading volume, of 169,300 shares, the days-to-cover ratio is currently 2.3 days.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright reiterated a “buy” rating and issued a $8.00 target price on shares of Bionomics in a report on Wednesday, June 12th.
View Our Latest Stock Report on Bionomics
Bionomics Stock Up 3.5 %
Bionomics Company Profile
Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder.
Featured Stories
- Five stocks we like better than Bionomics
- What is MarketRankā¢? How to Use it
- Qualcomm Stock: AI-Powered Growth Despite Volatility
- Investing In Preferred Stock vs. Common Stock
- Salesforce Stock: Meeting Recap, AI Focus, and Forecast
- What is Forex and How Does it Work?
- Is CAVA Overextended? A Closer Look at This High-Flying Stock
Receive News & Ratings for Bionomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bionomics and related companies with MarketBeat.com's FREE daily email newsletter.